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Abstract
Objectives: Low	ultraviolet-	B	 (UVB)	 radiation	causes	hypovitaminosis	D,	which	 is	a	
known	risk	factor	for	multiple	sclerosis	(MS)	and	associated	with	MS	disease	activity.	
Our objective is to test whether vitamin D supplementation is most effective in lower-
ing	disease	activity	during	the	period	of	the	year	with	low	UVB	radiation	and	conse-
quently	low	serum	25-	hydroxyvitamin	D3	(25(OH)D3)	concentration.
Methods: Retrospective analysis of medical records from our outpatient department 
identified	40	MS	patients	with	available	data	of	at	least	6	months	before	and	during	
oral	vitamin	D	supplementation.	Serum	25(OH)D3	concentration	was	analyzed	using	
immunoassay.	UVB	radiation	data	were	provided	by	the	local	government.	Annualized	
and quarterly relapse rates before and during vitamin D supplementation served as 
outcome parameters.
Results: During	vitamin	D	supplementation	(18,950	international	units/week	(mean,	SD 
3,397)),	serum	25(OH)D3	concentration	increased	by	51	nmol/L	and	the	UVB-	related	
seasonal	variability	in	25(OH)D3	levels	ceased	(rho	=	−0.13,	p	>	.05).	Furthermore,	the	
annualized	relapse	rate	decreased	by	approximately	50%.	This	was	almost	solely	driven	
by	 the	prominent	 reduction	 in	 the	quarterly	 relapse	 rate	 in	 late	winter/early	 spring,	
when	25(OH)D3 levels of nonsupplemented patients were the lowest.
Conclusions: Our	study	demonstrated	the	modulation	of	seasonal	MS	disease	activity	
through vitamin D supplementation. Given the prominent reduction in the quarterly 
relapse	rate	in	late	winter/early	spring,	our	data	indicate	a	beneficial	effect	of	supple-
menting	MS	patients	with	vitamin	D,	especially	during	this	period	of	the	year.
K E Y W O R D S
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1  | INTRODUCTION
Multiple	sclerosis	(MS)	is	a	chronic	autoimmune	disease	of	the	central	
nervous system and one of the most frequent neurological disorders 
in	young	adults	(Noseworthy,	Lucchinetti,	Rodriguez,	&	Weinshenker,	
2000).	 The	 generally	 recognized	 MS	 risk	 factor	 hypovitaminosis	 D	
(Ascherio	&	Munger,	2007;	Hanwell	&	Banwell,	 2011)	 is	defined	as	
a	 25-	hydroxyvitamin	 D	 (25(OH)D)	 concentration	 below	 50	nmol/L	
and	is	prevalent	in	approximately	57%	of	German	adults	(Hintzpeter,	
Mensink,	 Thierfelder,	 Müller,	 &	 Scheidt-	Nave,	 2008).	 Experimental	
data	 show	 that	 vitamin	 D	 (VD)	 possesses	 anti-	inflammatory	 and	
immunomodulatory properties through inhibition of dendritic cell 
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differentiation,	induction	of	T	regulatory	cells,	blockage	of	Th17	differ-
entiation,	and	down-	regulation	of	Th1	immune	responses	(Farias	et	al.,	
2013;	 Hamzaoui	 et	al.,	 2014;	 Lemire,	 Archer,	 Beck,	 &	 Spiegelberg,	
1995).	Concordantly,	 several	 studies	have	 found	an	 inverse	 correla-
tion	 between	 serum	25(OH)D	 concentration	 and	 disease	 activity	 in	
MS	patients	 (Brola	et	al.,	2016;	Pierrot-	Deseilligny,	Rivaud-	Péchoux,	
Clerson,	de	Paz,	&	Souberbielle,	2012;	Rotstein	et	al.,	2015;	Simpson	
et	al.,	 2010).	These	 findings	 are	 supported	by	genetic	 data	 showing	
that	the	MS	susceptibility	gene	HLA-	DRB1*1501	is	regulated	by	a	VD-	
dependent	promotor	(Ramagopalan	et	al.,	2009).
Ultraviolet-	B	(UVB)	radiation	(290–315	nm),	which	decreases	with	
greater	 distance	 from	 the	 equator,	 is	mandatory	 for	 the	 conversion	
of	 7-	dehydrocholesterol	 into	 previtamin	D3	 (Webb,	 Kline,	 &	Holick,	
1988).	Therefore,	populations	of	mid-	and	high-	latitude	countries	often	
lack	a	sufficient	supply	with	VD	and	have	a	higher	risk	of	developing	
MS	(Kimlin,	2008).	A	retrospective	data	analysis	conducted	in	France	
showed	an	association	between	regional	variation	 in	MS	prevalence	
and	UVB	 radiation	 (Orton	et	al.,	 2011).	While	UVB	 radiation	 is	 also	
thought	to	have	a	VD	independent	immunomodulatory	effect	(Breuer	
et	al.,	2014),	it	contributes	to	approximately	90%	of	the	body’s	25(OH)
D	supply	 (Federal	Office	 for	Radiation	Protection	 (Germany),	2012).	
Ascherio	et	al.	 reported	a	57%	 lower	 relapse	 rate	 in	patients	with	a	
higher	 25(OH)D	 concentration	 (Ascherio	 et	al.,	 2014).	 Furthermore,	
an	 analysis	 of	 the	 international	MSBase	 registry	 data	 demonstrated	
that increasing latitudes away from the equator are associated with 
a	shorter	lag	between	seasonal	UV	radiation	trough	and	relapse	peak	
(Spelman	et	al.,	2014).	The	relapse	peak	was	recorded	in	early	spring	
(March)	and	the	relapse	trough	in	autumn	(October),	which	indicate	an	
annual	cyclical	pattern	of	MS	disease	activity	(Spelman	et	al.,	2014).	As	
UVB	radiation	is	lowest	during	the	winter	months	(Webb	et	al.,	1988)	
and	25(OH)D3	has	a	half-	life	of	approximately	15	days	(Jones,	2008),	
VD	deficiency	increases	during	winter.	Consequently,	hypovitaminosis	
D has the most substantial impact on the immune system in late win-
ter/early spring.
To	our	knowledge	no	other	study	has	yet	examined	 the	 interac-
tions	 among	 seasonal	variations	 in	UVB	 radiation,	 serum	25(OH)D3 
concentration,	and	MS	relapse	rates	and	the	effect	of	VD	supplemen-
tation	on	these	associations.	We	aim	to	 investigate	whether	MS	re-
lapse	rates	are	higher,	when	UVB	radiation	and	consequently	25(OH)
D3	 levels	are	 low.	 If	this	 increase	 in	MS	disease	activity	 is	genuinely	
induced	by	hypovitaminosis	D,	 then	VD	supplementation	 should	be	
most effective during this period of the year.
2  | METHODS
2.1 | Patient group studied
Our	 retrospective	 medical	 chart	 analysis	 identified	 40	 MS	 patients	
with an observation period of at least 6 months before and after the 
initiation	of	VD	supplementation.	All	patients	were	 treated	between	
April	2010	and	June	2016	at	the	neurological	outpatient	department	
Neurocenter	 Peine,	 in	 Peine	 (latitude	 52.3,	 longitude	 10.2),	 Lower	
Saxony,	 Germany.	 Unless	 contraindicated,	 generally	 all	 MS	 patients	
from our outpatient department are recommended to take orally 
20,000	international	units	(IU)	of	VD	per	week.	This	is	well	below	the	
Food	and	Nutrition	Board’s	upper	tolerable	intake	limit	recommenda-
tion	 of	 4,000	IU/day	 (28,000	IU/week)	 (Institute	 of	Medicine,	 Food	
and	Nutrition	Board,	2010).	Patient	consultation	and	documentation	
was conducted by MM. Data were retrospectively assessed by MM 
and	AM.	VD	status	was	determined	by	measuring	the	serum	25(OH)
D3 concentration in a local laboratory using chemiluminescent immu-
noassay. If different immunotherapies were used in the predefined 
intervals	 (before	 and	 during	 VD	 supplementation),	 the	 MS	 therapy	
with the longest duration in each interval was defined as concomitant 
immunotherapy.	Following	the	German	MS	guidelines,	a	relapse	was	
defined	as	a	worsening	of	clinical	symptoms,	which	was	not	related	to	
any	other	infectious	disease	or	condition	and	lasted	more	than	24	hr	
(Gold,	2012).
2.2 | UVB radiation
We	 received	 the	 local	 (latitude	52.2,	 longitude	9.1)	 erythemal	UVB	
radiation	 (mW/m²)	 data	 from	 the	 ministry	 of	 environment,	 energy,	
and	climate	protection	of	Lower	Saxony.	UVB	radiation	was	recorded	
from	April	2010	to	June	2016.	Mean	UVB	values	were	calculated	for	
each	month	and	each	quarter	of	the	year	(January–March,	April–June,	
July–September,	and	October–December).
2.3 | Endpoints
Efficacy	 endpoints	 were	 the	 individually	 analyzed	 quarterly	 (QRR)	
and	 annualized	 relapse	 rate	 (ARR).	 The	 ARR	was	 calculated	 by	 di-
viding the total number of relapses by the observed time in years. 
Calculation	 of	 the	 QRR	 was	 based	 on	 the	 monthly	 relapse	 rates,	
which were calculated by dividing the cumulative number of relapses 
by the total number of the respective month during the entire obser-
vation	period.	Afterward,	the	monthly	relapse	rates	of	each	quarter	
were summed.
2.4 | Statistical analysis
We	performed	a	descriptive	analysis,	which	included	all	evaluable	pa-
tients.	Missing	values	were	not	imputed.	The	Kruskal–Wallis	test	was	
used	to	assess	the	different	quarterly	distributions	of	the	year’s	UVB	
radiation.	Regarding	the	comparison	of	serum	25(OH)D3 levels before 
and	during	VD	supplementation,	we	followed	Hintzpeter	et	al.’s	pro-
posal and ran a seasonal deconvolution to control for the month of 
sampling	(Hintzpeter	et	al.,	2008).	Using	Spearman’s	correlation	coef-
ficient,	we	separately	investigated	the	patients’	data	before	and	during	
VD	supplementation	to	identify	the	effect	of	VD	supplementation	on	
the	association	between	UVB	radiation	and	serum	25(OH)D3 concen-
tration.	The	Wilcoxon	signed-	rank	test	was	used	to	investigate	the	ARR	
and	 QRR	 before	 and	 during	 VD	 supplementation.	 Statistical	 signifi-
cance was declared for p	<	.05	and	illustrated	in	the	figures	using	“*”.	 
A	p-	value	<	.01	was	depicted	as	“**”.	All	analyses	were	performed	using	
SPSS	Statistics	20®	(IBM	Corporation:	Armonk,	New	York,	USA).
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2.5 | Ethical approval
The present retrospective data analysis was in accordance with the 
ethic	committee	of	the	medical	association	of	Lower	Saxony,	Germany.
3  | RESULTS
The baseline characteristics of the study population are presented 
in	 Table	1.	 The	 serum	 samples	 of	 25(OH)D3 measurements were 
obtained	2	years	(mean,	SD	1)	after	the	initiation	of	VD	supplemen-
tation.	 Patients	 received	 a	mean	VD	dose	of	 18,950	IU	per	week	
(SD	3,397),	which	increased	the	mean	serum	25(OH)D3 concentra-
tion	by	51.4	nmol/L	(Table	1).	The	year’s	UVB	radiation	differed	sig-
nificantly	as	higher	values	were	recorded	from	April	to	September	
and	lower	values	were	recorded	from	October	to	March	(Figure	S1).	
Before	VD	supplementation,	we	found	a	strong	correlation	between	
the	monthly	UVB	radiation	at	sampling	and	serum	25(OH)D3 con-
centration	(rho	=	0.41,	p	<	.01,	number	of	25(OH)D3 measurements: 
47).	Consequently,	serum	25(OH)D3	levels	of	nonsupplemented	MS	
patients	showed	seasonal	variations	exhibiting	a	peak	from	July	to	
September	 (Figure	S1),	which	 labels	 the	end	of	 the	period	of	high	
UVB	exposure	(Figure	S1).	This	was	the	only	period	of	the	year	dur-
ing	 which	 serum	 25(OH)D3	 levels	 of	 non-	supplemented	 patients	
were	above	the	lower	limit	of	normal	(50	nmol/L	(Hintzpeter	et	al.,	
2008)).	 In	 contrast,	 during	VD	 supplementation,	 serum	25(OH)D3 
levels	 remained	 steadily	 above	 70	nmol/L	 and	 the	 seasonal	 fluc-
tuations	 ceased	 (Figure	1).	 The	 correlation	 between	 UVB	 radia-
tion	and	serum	25(OH)D3 concentration was no longer significant 
(rho	=	−0.13,	p	=	.33,	number	of	25(OH)D3	measurements:	62).
In	 comparison	 to	before	 supplementation,	 the	ARR	was	 approxi-
mately	50%	lower	during	VD	supplementation	(Figure	2a),	which	was	
driven by the significantly lower QRR in the first quarter of the year 
(January–March)	(Figure	2b).	Before	VD	supplementation,	also	the	low-
est	serum	25(OH)D3	levels	were	measured	in	the	period	from	January	
to	 March	 (Figure	1).	 By	 excluding	 this	 period	 from	 the	 relapse	 rate	
calculation,	 the	 difference	 in	 relapse	 rates	was	 no	 longer	 significant	
(Figure	2a).	 A	 multivariate	 cross-	sectional	 linear	 regression	 analysis,	
which	included	the	ARR	as	outcome	variable	and	VD	supplementation,	
immunotherapies,	MS	phenotype,	gender,	age,	and	disease	duration	as	
independent	variables,	proved	that	VD	supplementation	has	a	signifi-
cant	effect	on	MS	disease	activity	(regression	coefficient	for	VD	sup-
plementation,	−0.24;	95%	confidence	interval,	−0.61	to	−0.02;	p	=	.04).
4  | DISCUSSION
Investigating	 the	 effect	 of	 VD	 supplementation	 on	 the	 interactions	
between	 seasonal	 variations	 in	 UVB	 radiation,	 serum	 25(OH)D3 
TABLE  1 Baseline	characteristics
Baseline characteristics Mean SD N
Age	at	MS	diagnosis	(in	years) 33.9 11.8 40
Age	at	first	consultation	(in	years) 42.1 11.0 40
Age	at	start	of	VD	supplementation	(in	
years)
44.1 11.0 40
EDSS	score	at	start	of	VD	supplementation 3.1 1.5 39
VD	dose	(in	international	units/week) 18,950 3,397 40
Gender % N
Female 60 — 24
MS	phenotype % N
RRMS 75 — 30
PRMS 25 — 10
Before VD During VD p- value
Additional	information
Serum	25(OH)D3	levels	(mean	
(SD)	(in	nmol/L)),	n	=	26a
38.7	(24.1) 90.1	(27.1) <.001b
Time	of	follow	up	(mean	(SD)	
(in	years)),	n	=	40
2.0	(1.4) 2.6	(1.2) n.s.b
Immunotherapy
Interferons 35% 30% n.s.c
No therapy 30% 22.5% n.s.c
Glatiramer acetate 17.5% 20% n.s.c
Natalizumab 10% 17.5% n.s.c
Immunosuppressants 5% 2.5% n.s.c
Glucocorticoids 2.5% 2.5% n.s.c
Dimethyl fumarate 0% 5% n.s.cs
EDSS,	 Expanded	 disability	 status	 scale;	 MS,	 Multiple	 sclerosis;	 n.s.,	
Nonsignificant;	 PR,	 Progressive	 relapsing;	 RR,	 Relapsing	 remitting;	 VD,	
Vitamin	D;	25(OH)D3,	25-	hydroxyvitamin	D3.
aIncluded	 were	 only	 patients	 with	 available	 25(OH)D3 measurements 
before	and	during	VD	supplementation.
bWilcoxon	signed-	rank	test.
cChi-	square.
F IGURE  1 Serum	25(OH)D3 concentration before and during 
vitamin	D	supplementation.	White	bars:	Before	VD	supplementation,	
grey	bars:	During	VD	supplementation.	N:	January–March:	Before	
VD	12,	during	VD	11;	April–June:	Before	VD	8,	during	VD	10;	July–
September:	Before	VD	11,	during	VD	18;	October–December:	Before	
VD	12,	during	VD	12.	Abbreviations:	SE,	Standard	error;	VD,	Vitamin	
D;	25(OH)D3,	25-	hydroxyvitamin	D3
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concentration,	and	MS	disease	activity,	we	demonstrated	that	relapse	
rates were higher and more subject to seasonal fluctuations before 
the	 supplementation	 with	 VD.	 VD	 supplementation	 had	 the	 great-
est	effect	on	relapse	rates	in	the	first	quarter	of	the	year,	when	UVB	 
radiation	 and	 consequently	 25(OH)D3 levels of nonsupplemented 
patients were low.
Through	 oral	 supplementation	 with	 VD	 (18,950	IU	 per	 week	
[mean,	 SD	 3,397]),	 serum	 25(OH)D3 levels increased significantly 
by	 approximately	 51	nmol/L	 (Table	1).	 Similarly,	 a	 prospective	 co-
hort	 study	 from	 Finland	 reported	 an	 increase	 of	 56	nmol/L	 after	
supplementing	patients	with	20,000	IU	of	VD	per	week	for	12	months	
(Soilu-	Hänninen	et	al.,	2012).
In	 our	 study	 cohort,	 the	ARR	 decreased	 by	 approximately	 50%	
after	the	initiation	of	VD	supplementation.	In	comparison,	Burton	et	al.	
reported	 a	 slightly	 lower	 reduction	 in	 the	ARR	 (41%)	 (Burton	 et	al.,	
2010).	The	patients	included	in	our	study	were	supplemented	with	VD	
regardless	of	their	baseline	serum	25(OH)D3	concentration.	Therefore,	
we	cannot	rule	out	that	also	patients	with	sufficient	25(OH)D3 levels 
were	enrolled.	It	is	more	likely,	however,	that	this	would	have	led	to	a	
reduced	rather	than	an	increased	effect	of	VD	supplementation.
F IGURE  2 Relapse rates before and 
during	vitamin	D	supplementation.	(a)	
relapse rates with and without the first 
quarter.	Included	patients	per	year,	before//
during	VD	supplementation:	40//40.	
Statistics:	Wilcoxon	signed-	rank	test.	(b)	
Relapse rates of quarterly periods. White 
bars:	Before	VD	supplementation.	Grey	
bars:	During	VD	supplementation.	Included	
patients	per	quarter,	before//during	VD	
supplementation:	quarter	1:	40//40,	quarter	
2:	40//39,	quarter	3:	39//39,	quarter	4:	
36//39.	Statistics:	Wilcoxon	signed-	rank	
test.	Abbreviations:	n.s.,	Nonsignificant;	SE,	
Standard	error;	VD,	Vitamin	D
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The	 effect	 of	 VD	 supplementation	 on	 MS	 disease	 activity	 was	
most	prominent	in	late	winter/early	spring	(January–March),	which	is	
the	period	of	the	year	with	low	UVB	radiation	and	the	lowest	serum	
25(OH)D3	concentration.	Interestingly,	we	did	not	observe	an	increase	
in	disease	activity	from	October	to	December,	when	UVB	radiation	is	
low	as	well	and	25(OH)D3	 levels	start	to	decline.	An	epidemiological	
study supports this finding demonstrating that the increase in relapse 
rate	lagged	1.5	months	behind	the	local	UVB	radiation	(Tremlett	et	al.,	
2008).	Therefore,	UVB	radiation	of	late	summer	might	also	influence	
relapses	in	the	fourth	quarter	of	the	year.	The	approximately	15-	day	
half-	life	of	25(OH)D3	might	play	a	key	role	in	this	lag	(Jones,	2008).	As	
our	work	was	a	purely	retrospective	study	of	medical	records,	we	can-
not	provide	seasonal	 immunological	data	to	support	our	explanation	
for the lag in relapse rates. Immunological alterations induced by hy-
povitaminosis	D	such	as	suppression	of	inflammatory	cytokines,	stim-
ulation	of	T-	regulatory	and	Th2-	cell	differentiation,	inhibition	of	B-	cell	
development,	and	modulation	of	the	Nf-	kappa-	B	pathway	(Szymczak	
&	Pawliczak,	2016)	might	appear	earlier	 than	 the	clinical	effects—in	
our	case	the	increase	in	ARR.	The	lack	of	laboratory	investigations	is	
therefore the major weakness of our study and should be considered 
while interpreting the epidemiological data.
Before	VD	 supplementation,	 patients	 also	 demonstrated	 a	 peak	
of	relapse	rates	from	July	to	September,	which	was	not	paralleled	by	
25(OH)D3 deficiency. This relapse peak points to additional triggering 
factors	of	disease	activity	aside	from	UVB	radiation	and	serum	25(OH)
D3	concentration.	Oqawa	G	et	al.	demonstrated	in	a	Japanese	cohort	
of	MS	patients	that	relapse	rates	had	two	peaks	over	the	year:	one	in	
the	winter	and	one	the	in	summer	(Oqawa	et	al.,	2004).	The	summer	
peak	in	relapse	rates	was	explained	by	higher	temperatures	leading	to	
immunological	modulations,	 in	 particularly	 to	 a	 change	 in	 leukocyte	
nitric-	oxide	production	(Beenakker	et	al.,	2001;	Oqawa	et	al.,	2004).	A	
complementary	immunological	explanation	from	a	recently	conducted	
study	 are	 the	 summer	 troughs	 of	melatonin	 production,	which	 ulti-
mately	 lead	 to	 the	 induction	of	pathogenic	Th17-	cell	differentiation,	
inhibition	 of	 protective	 T-	regulatory	 cells,	 and	 deactivation	 of	 IL-	10	
promotors	(Farez	et	al.,	2015).	Further	studies	are	warranted	to	clarify	
these hypotheses as possible reasons for the increase in relapse rates 
during summer.
Retrospective studies are generally limited in their validity. 
However,	we	have	no	evidence	for	biases	often	associated	with	retro-
spective	study	designs,	for	example,	selection	or	information	bias.	To	
check	for	the	selection	bias,	we	compared	the	baseline	characteristics	
of	 included	patients	 (≥6	months	follow-	up,	n	=	40)	with	the	baseline	
characteristics	of	all	other	MS	patients	from	the	outpatient	department	
(n	=	65).	In	this	comparison,	we	did	not	find	significant	differences	be-
tween	both	patient	groups	regarding	age,	gender,	MS	phenotype,	ARR,	
and	score	on	the	expanded	disability	status	scale.	An	information	bias	
is unlikely because patient consultation and documentation was con-
ducted	by	only	one	physician	(MM).	Also,	a	regression	to	the	mean	ef-
fect	appears	unlikely	as	the	initiation	of	VD	supplementation	was	not	
driven	by	disease	activity,	which	is	supported	by	the	inclusion	of	15/40	
patients	who	were	relapse	free	before	the	start	of	VD	supplementa-
tion.	Furthermore,	the	correlation	analysis	between	UVB	radiation	and	
serum	25(OH)D3	concentration	needs	clarification.	As	indicated	by	the	
included	data	points,	some	patients	had	more	than	one	observation	in	
this	correlation	analysis.	Consequently,	some	individuals	possibly	con-
tributed	more	than	others	to	the	observed	effect.	However,	as	UVB	
radiation	contributes	 to	approximately	90%	of	 the	body’s	25(OH)D3 
supply	(Federal	Office	for	Radiation	Protection	(Germany),	2012),	we	
conclude	that	seasonal	UVB	radiation	has	a	stronger	impact	on	serum	
25(OH)D3 levels than the effects caused by each individual patient. 
Our conclusion is supported by a correlation analysis between the 
mean	values	of	serum	25(OH)D3	levels	and	the	mean	concurrent	UVB	
radiation,	which	precludes	 the	 inclusion	of	more	 than	one	observa-
tion	per	patient	(prior	VD	supplementation:	rho	=	0.42,	p	=	.01,	n	=	35;	
during	VD	supplementation:	rho	=	−0.24,	p	=	.19,	n	=	32).	Lastly,	 im-
munotherapies	 differed	 between	 observation	 periods,	 which	 might	
have	a	major	effect	on	the	ARR	as	our	outcome	parameter.	However,	
our	multivariate	cross-	sectional	linear	regression	analysis	proved	that	
VD	supplementation	has	a	significant	effect	on	MS	disease	activity.
Altogether,	our	data	indicate	that	VD	supplementation	has	bene-
ficial	effects	on	MS	disease	activity	and	that	these	effects	are	higher	
during	seasons	with	low	UVB	radiation	and	consequently	insufficient	
25(OH)D3	supply.	Therefore,	our	data	argue	for	an	intensified	VD	sup-
plementation	in	MS	patients,	especially	during	winter	and	early	spring.	
Regarding	 the	seasonality	of	VD	efficacy,	upcoming	VD	supplemen-
tation studies should adjust their efficacy analysis for the different 
seasons	of	the	year.	Furthermore,	future	research	should	focus	on	the	
identification	 of	 additional	 triggering	 factors	 of	MS	disease	 activity.	
Ideally—as	 is	 the	 case	 with	 VD—these	 factors	 could	 be	 modulated	
therapeutically.	 In	addition	to	standard	medication,	 this	would	allow	
supportive therapies adjusted for the specific immunological demands 
during different seasons of the year.
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